ClinicalTrials.gg
CompletedNCT01991821Updated Aug 20, 2019Results posted

European Phase III Study of APD421 in PONV

A Phase 3 interventional study of APD421 and Placebo in PONV, sponsored by Acacia Pharma Ltd. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Acacia Pharma Ltd · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing amisulpride in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Amisulpride · Postoperative Nausea and Vomiting.

Enrollment
7th of 11
368 · median 453
Started
2013
with 1 other
Phase 3
6 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
8 of 11
Acacia Pharma Ltd

Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 2nd registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

2 of the 11 studies testing amisulpride in Postoperative Nausea and Vomiting are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About amisulpride

Amisulpride: first FDA approval 2020 (BARHEMSYS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing amisulpride in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age
  • Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure and expected to require at least one overnight stay in hospital

Exclusion criteria

Exclusion Criteria:

  • Patients scheduled for outpatient/day case surgery
  • Patients scheduled to undergo intra-thoracic, transplant or central nervous system surgery
  • Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block
  • Patients who are expected to remain ventilated for a period after surgery
  • Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
368 participants (actual)

Study arms

  • Experimental
    APD421

    IV APD421 single dose

    Drug: APD421

  • Placebo comparator
    Placebo

    IV placebo single dose

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Response (no Emesis, Significant Nausea or Rescue Medication)

    The primary efficacy analysis was a comparison of the incidence of Complete Response (absence of PONV1) in the 0-24-hour period after surgery, between the active treatment group and the placebo group using Pearson square test with Yates's continuity correction at a two-sided significance level of 5%.

    Time frame: 24 hours after end of surgery

Secondary outcomes

  1. Complete Response (no Emesis or Rescue Medication)

    Time frame: 24 hrs after end of surgery

  2. Total Response (no Emesis, Nausea or Rescue Medication)

    Time frame: 24 hrs after end of surgery

  3. Incidence of Emesis (Vomiting/Retching)

    An assessment of a participant experiencing an episode of emesis (vomiting/ retching) or received anti-emetic rescue medication during the 24hours after the completion of the surgery

    Time frame: 24 hours after end of surgeryry

  4. Incidence of Nausea

    Count of patients experiencing an episode of nausea scored ≥ 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery

    Time frame: 24 hours after end of surgery

  5. Incidence of Significant Nausea

    Count of participants with nausea score ≥ 4 on 0-10 verbal response scale

    Time frame: 24 hours after end of surgery

  6. Use of Rescue Medication

    Time frame: 24 hours after end of surgery

07

Results

Posted Aug 2, 2019
Limitations and caveats
There are no limitations and caveats with this study.

Participant flow

Participant flow — Overall Study
MilestoneAPD421Placebo
Started169178
Completed611
Not completed163167

Outcome measures

PrimaryComplete Response (no Emesis, Significant Nausea or Rescue Medication)

The primary efficacy analysis was a comparison of the incidence of Complete Response (absence of PONV1) in the 0-24-hour period after surgery, between the active treatment group and the placebo group using Pearson square test with Yates's continuity correction at a two-sided significance level of 5%.

Time frame:
24 hours after end of surgery
Reported as:
Count of participants · Participants
Complete Response (no Emesis, Significant Nausea or Rescue Medication)
ParticipantsAPD421Placebo
Complete Response (no Emesis, Significant Nausea or Rescue Medication)9583
Statistical analysis
  • APD421 vs Placebo · Chi-squared, Corrected · p = 0.093 (The complete response of the primary efficacy analysis occurred in 95 patients (56.2%; 95% confidence interval \[CI\] 48.4 - 63.8%) in the APD421 group and 83 patients (46.6%; 95% CI 39.1- 54.2%) in the placebo group)Pearson square test with Yates's continuity correction and with the two- sided significance level of 5%
SecondaryComplete Response (no Emesis or Rescue Medication)
Time frame:
24 hrs after end of surgery
Reported as:
Count of participants · Participants
Complete Response (no Emesis or Rescue Medication)
ParticipantsAPD421Placebo
Complete Response (no Emesis or Rescue Medication)10089
Statistical analysis
  • APD421 vs Placebo · Chi-squared, Corrected · p = 0.059 (Two-sided, significance threshold = 0.05)
SecondaryTotal Response (no Emesis, Nausea or Rescue Medication)
Time frame:
24 hrs after end of surgery
Reported as:
Count of participants · Participants
Total Response (no Emesis, Nausea or Rescue Medication)
ParticipantsAPD421Placebo
Total Response (no Emesis, Nausea or Rescue Medication)8773
Statistical analysis
  • APD421 vs Placebo · Chi-squared, Corrected · p = 0.053 (Two-sided, significance threshold = 0.05)
SecondaryIncidence of Emesis (Vomiting/Retching)

An assessment of a participant experiencing an episode of emesis (vomiting/ retching) or received anti-emetic rescue medication during the 24hours after the completion of the surgery

Time frame:
24 hours after end of surgeryry
Reported as:
Count of participants · Participants
Incidence of Emesis (Vomiting/Retching)
ParticipantsAPD421 at 5mgPlacebo
Incidence of Emesis (Vomiting/Retching)3446
Statistical analysis
  • APD421 at 5mg vs Placebo · Chi-squared, Corrected · p = 0.26 (Two-sided, significance threshold = 0.05)
SecondaryIncidence of Nausea

Count of patients experiencing an episode of nausea scored ≥ 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery

Time frame:
24 hours after end of surgery
Reported as:
Count of participants · Participants
Incidence of Nausea
ParticipantsAPD421 at 5mgPlacebo
Incidence of Nausea7598
Statistical analysis
  • APD421 at 5mg vs Placebo · Chi-squared, Corrected · p = 0.06 (Two-sided, significance threshold = 0.05)
SecondaryIncidence of Significant Nausea

Count of participants with nausea score ≥ 4 on 0-10 verbal response scale

Time frame:
24 hours after end of surgery
Reported as:
Count of participants · Participants
Incidence of Significant Nausea
ParticipantsAPD421Placebo
Incidence of Significant Nausea6384
Statistical analysis
  • APD421 vs Placebo · Chi-squared, Corrected · p = 0.079 (Two-sided, significance threshold = 0.05)
SecondaryUse of Rescue Medication
Time frame:
24 hours after end of surgery
Reported as:
Count of participants · Participants
Use of Rescue Medication
ParticipantsAPD421Placebo
Use of Rescue Medication6282
Statistical analysis
  • APD421 vs Placebo · Chi-squared, Corrected · p = 0.096

Adverse events

Collected over Any AE that is serious occurring during the course of the study, irrespective of the treatment received by the subject must be reported to the pharmacovigilance provider within 24hours of it's recognition. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
APD421 at 5mg0/169 (0%)3/169 (1.8%)91/169 (53.8%)
Placebo0/178 (0%)4/178 (2.2%)178/178 (100%)
Most frequent serious events
Most frequent serious events
EventAPD421 at 5mgPlacebo
Anastomic LeakInjury, poisoning and procedural complications1/1690/178
Portal Vein ThrombosisHepatobiliary disorders1/1690/178
AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1690/178
Gastrointestinal Stoma ComplicationInjury, poisoning and procedural complications0/1691/178
Post Procedural HaemorrhageInjury, poisoning and procedural complications0/1691/178
PresyncopeNervous system disorders0/1691/178
HaemorrhageVascular disorders0/1691/178
Most frequent other events
Most frequent other events
EventAPD421 at 5mgPlacebo
Procedural PainInjury, poisoning and procedural complications91/16992/178
NauseaGastrointestinal disorders20/16918/178
FlatulenceGastrointestinal disorders18/16916/178
Blood Prolactin IncreasedInvestigations18/1692/178
ConstipationGastrointestinal disorders16/1699/178
HeadacheNervous system disorders14/1699/178
HypotensionVascular disorders9/16914/178
AnaemiaBlood and lymphatic system disorders10/1699/178
Sleep DisorderPsychiatric disorders7/1699/178

Baseline characteristics

Age, Continuous
Age, Continuous(Years)APD421PlaceboTotal
Mean51.7 ± 16.251.6 ± 14.951.6 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)APD421PlaceboTotal
Female147154301
Male222446
08

Study locations

2 sites
  • CHU de Hautepierre
    Strasbourg, France
  • University Hospitals of Würzburg
    Würzburg, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2019, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2013
First posted
Nov 25, 2013
Start
Jul 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Aug 2, 2019
Last update
Aug 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01991821
Lead sponsor
Acacia Pharma Ltd
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Jul 2013
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Aug 2, 2019
Last update
Aug 20, 2019

Study contacts

Pierre Diemunsch, MD
principal investigator · Hôpital de Hautepierre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amisulpride

Start the discussion